🧠Oruen CNS Weekly Roundup: The Latest in CNS Medicine 🧠Â
The field of CNS medicine continues to advance across a wide range of neurological and psychiatric conditions. This week’s roundup highlights new research spanning psychiatry, neurodegeneration, neuro-oncology, headache, and interventional neuroscience.
Depression: Psilocybin-assisted therapy shows clinical benefit
Recent clinical trial data published in JAMA Psychiatry demonstrate that psilocybin-assisted therapy can lead to meaningful reductions in depressive symptoms in patients with treatment-resistant depression. These findings support the growing role of psychedelic-assisted therapies as a potential new approach in psychiatric care.
Continue reading here:
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2846478
Schizophrenia: Muscarinic-targeting antipsychotics show promise
A recent Lancet network meta-analysis highlights the efficacy of muscarinic receptor-targeting antipsychotics in reducing symptoms of schizophrenia, potentially offering an alternative to traditional dopamine-based therapies with a different side effect profile.
Continue reading here:
https://www.sciencedirect.com/science/article/pii/S0140673625023657
Alzheimer’s Disease: Semaglutide investigated in early disease
New data from the EVOKE and EVOKE+ trials reported in The Lancet explore the use of oral semaglutide in early Alzheimer’s disease, reflecting growing interest in metabolic and neuroprotective approaches to slowing disease progression.
Continue reading here:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2900459-9/fulltext
Headache / Migraine: Optimising preventive treatment strategies
A recent Lancet Neurology article highlights the ongoing need to optimise migraine prevention, including the integration of CGRP-targeting therapies and improved treatment pathways to enhance patient outcomes.
Continue reading here:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2826%2900041-4/fulltext
Stroke: OCEANIC-STROKE trial informs secondary prevention
New findings from the OCEANIC-STROKE trial, reported by NeurologyLive, provide further insights into secondary prevention strategies following ischemic stroke or transient ischemic attack, contributing to evolving post-stroke management approaches.
Continue reading here:
https://www.neurologylive.com/view/results-of-oceanic-stroke-trial-for-secondary-stroke-prevention
Multiple Sclerosis: Fenebrutinib shows positive Phase 3 results
A Phase 3 study reported by NeurologyLive demonstrates that fenebrutinib met its primary endpoint in relapsing multiple sclerosis, highlighting the potential of BTK inhibition as a novel therapeutic mechanism in MS.
Continue reading here:
Epilepsy: Zorevunersen shows promise in Dravet syndrome
An international clinical trial highlighted by UCL reports that zorevunersen may significantly reduce seizure frequency in children with Dravet syndrome, supporting the advancement of precision genetic therapies in epilepsy.
Continue reading here:
https://www.ucl.ac.uk/news/2026/mar/life-changing-drug-identified-children-rare-epilepsy
Neuroradiology: AI enhances prediction of neurodevelopmental outcomes
New research presented by RSNA demonstrates that deep learning applied to cranial ultrasound imaging may improve early prediction of neurodevelopmental impairment in preterm infants, highlighting the growing role of AI in neuroradiology.
Continue reading here:
https://www.rsna.org/news/2026/march/cranial-ultrasound-in-preterm-infants
0 Comments